Safety of low lipoprotein(a) levels: the FOURIER trial
Eur Heart J. 2026 Jun 3:ehag398. doi: 10.1093/eurheartj/ehag398. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: Lipoprotein(a) (Lp(a)) is considered a causal risk factor for atherogenesis. A higher prevalence of certain adverse events, including diabetes mellitus (DM), has been reported for pati

